Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q3 FY19 Earnings Presentation
19 slides from Dr. Lal Pathlabs's earnings presentation, Feb 8, 2019
Slide 1: Exchange filing cover letter for investor presentation
February 8,201 9 The National Stock Exchange of India Limited The Bombay Stock Exchange Limited Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Bandra (E) Dalal Street, Mumbai - 400051 Mumbai - 400001 Subject: lnvestors Presentation on Unaudited Financial Results (Standalone and Consol
Slide 2: Q3 & 9M FY19 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q3 & 9M FY19 Results Presentation February 08, 2019
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Q3 FY19 Snapshot
Q3 FY19 Snapshot 11.3% Revenues INR 2,925 mn Samples Processed ~10.2 mn 16.3% Normalised INR 706 mn Patients Tested ~4.28 mn EBITDA 27% PAT INR 461 mn Total Employees* ~4,316 *As on March 31, 2018, 3
Slide 5: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Performance Highlights 3 Financial Table 4 Financial Highlights 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Corporate Overview 9 Shareholding 10 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at
Slide 6: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs 193 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi and Regional Ref lab at diagnostic services Kolkata), 2,153 Patient Service Centers (PSCs) and 5,624 Pick-up Points (PUPs)* Scalable model integrated Catalogue of 478 te
Slide 7: Key Performance Highlights
Key Performance Highlights Consistent growth in patient and samples volumes for Q3 at 12.1% and 17.3% respectively driving revenue growth for the quarter During Q3 FY19: • Revenues gained 11.3% YoY to Rs 2,925 million following 12.1% increase in patient volumes • Number of patients tested stood at 4
Slide 8: Financial Table
Financial Table Particulars (Rs. mn) Q3 FY19 Q3 FY18 Growth % 9M FY19 9M FY18 Growth % Total Revenue 2,925 2,627 11.3% 9,023 7,901 14.2% Total Expenditure 2,269 2,061 6,749 5,901 EBITDA 656 566 15.9% 2,274 2,000 13.7% Adj for stock based comp. & CSR Cost 50 41 130 95 Normalised operating EBITDA 706
Slide 9: Financial Highlights
Financial Highlights Revenues All figures in Rs. mn Q3 saw 11.3% improvement in revenues at 9,023 Rs. 2,925 million. This was the result of: 7,901 • Consistent momentum in volumes with 2,925 2,627 12.1 % growth • Gains in tests per patient from 2.28 to 2.38 Q3FY19 realisation per patient stood a
Slide 10: Financial Highlights
Financial Highlights PBT All figures in Rs. mn Q3 PBT was at Rs. 679 million vs. Rs. 2,314 679 1,993 555 million last year 555 Q3 PBT margin was at 23.2% from 21.1% last year 9M PBT came in at Rs. 2,314 million with margins of 25.6% Q3 FY18 Q3 FY19 9M FY18 9M FY19 PAT Q3 PAT came in at Rs. 4
Slide 11: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs 2,153 No. of PUPs 1,759 189 193 1,559 164 172 1,340 5,668 5,624 4,967 5,021 FY15 FY16 FY17 FY18 FY15 FY16 FY17 FY18 FY15 FY16 FY17 FY18 No. of patients (mn) No. of samples (mn) 15.2 13.3 13.3 34.7 12.0 29.3 31.2 9.9 26.3 21.7 FY15 FY16 FY
Slide 12: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; "I am pleased with the direction of progress that the DLPL brand is taking. As a premier healthcare services brand, our focus is to drive quality initiatives and services to the patien
Slide 13: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services Initiatives to improve brand con
Slide 14: Corporate Overview
Corporate Overview • DLPL Strategy for future growth • Experienced Management team 13
Slide 15: DLPL Strategy for future growth
DLPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 14
Slide 16: DLPL Strategy for future growth
DLPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Lif
Slide 17: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Chairman and Managing Director Whole-time Director and Chief Whole-time Director Executive Officer Ved Prakash Goel Bharath Uppiliappan Shankha Banerjee Chief Financial Officer CEO India Business Chief Growth O
Slide 18: Shareholding as of 31st December, 2018
Shareholding as of 31st December, 2018 56.9% 8.4% Promoter and Promoter Mutual Group Funds* 16.7% 18.0% FII Others *Mutual Funds includes Alternate Investment Funds as well 17
Slide 19: Contact us
Contact us About Dr Lal PathLabs Limited (DLPL) For further information please contact: Dr Lal PathLabs Limited is one of India‟s leading consumer healthcare brand in diagnostic services. Ved Goel / Rajat Kalra It has an integrated nationwide network, where patients Dr. Lal PathLabs Limited and heal